Interna

[Comment] Astegolimab and the new era of biologics in COPD care

VIP article

Chronic obstructive pulmonary disease (COPD) affects 480 million people worldwide and this is projected to increase to nearly 600 million over the next two decades.1 Long-acting beta agonists (LABA) and long-acting muscarinic antagonists (LAMA), often combined with inhaled corticosteroids (ICS), are the cornerstone of

ME

MedScopeGlobal Editorial

May 28, 2026

InternaVIP

Evidence-based clinical briefing

[Comment] Astegolimab and the

MedScope VIP

This article is reserved for VIP subscribers. Upgrade for full access, an ad-free reading experience, and priority clinical alerts.

View membership options

Related coverage

Interna

Evidence-based summary

[Comment] Measuring mental disorder

Interna

[Comment] Measuring mental disorder burden for action

Quantifying the burden of mental disorders is essential, yet inherently reductive. Metrics such as disability-adjusted life-years (DALYs) and years lived with disability (YLDs) provide a highly important common framework for comparing diseases across settings, but they only partly reflect lived experience. Such figures

MedScopeGlobal EditorialMay 27, 2026